Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Transgene Biotek Ltd.
Source DateBoard Meeting DateDetails
31-Oct-2025 14-Nov-2025 Quarterly Results
30-Jul-2025 07-Aug-2025 Quarterly Results
28-Apr-2025 07-May-2025 Audited Results
17-Jan-2025 24-Jan-2025 Quarterly Results
04-Nov-2024 12-Nov-2024 Quarterly Results & A.G.M.
19-Jul-2024 10-Aug-2024 Quarterly Results
13-May-2024 30-May-2024 Quarterly Results & Audited Results
29-Jan-2024 14-Feb-2024 Quarterly Results
06-Nov-2023 14-Nov-2023 Quarterly Results & Inter alia, to consider and approve:- 2. To consider and approve the appointment of M/s.Vasavi & Co, chartered Accountants as Statutory Auditors of the Company for a period of Five years from the financial year 2023-24 upto-2027-2028, subject to the approval of members in the ensuing annual general meeting. 3. To consider and approve the appointment of M/s.Manisha Dubey, as internal auditor of the Company for financial year 2023-24. 4. To consider and approve the Notice of the 33 rd Annual General meeting for the Financial Year 2022-2023 and other related matters thereto. 5. To consider and approve Directors? Report and the annexure thereon for the Financial Year 2022-2023. 6. To transact such other business as may be required.
17-Jul-2023 05-Aug-2023 Quarterly Results Inter alia, to consider :- 1) To consider and approve the closure of subsidiary company M/s. Peroral Bio Private Limited. 2) To consider and approve an extension for the date of Annual General Meeting (AGM) of the Company for the financial year 2022-23. 3) To consider and approve the appointment of M/s Geeta Serwani & Associates, as Secretarial Auditor of the Company for the financial year 2022-23. 4) To consider and approve the appointment of Ms. Vasavi & Co, as Internal Auditors of the Company for the financial year 2022-23. 5) To transact such other business as may be required.
12-May-2023 30-May-2023 Audited Results
27-Jan-2023 14-Feb-2023 Quarterly Results
04-Nov-2022 12-Nov-2022 Quarterly Results
20-Jul-2022 13-Aug-2022 Quarterly Results & A.G.M.
04-May-2022 30-May-2022 Audited Results
31-Jan-2022 14-Feb-2022 Quarterly Results
03-Nov-2021 12-Nov-2021 Quarterly Results
05-Aug-2021 14-Aug-2021 Quarterly Results
21-Jun-2021 29-Jun-2021 Audited Results Inter alia, 1) To consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended on 31 st March 2021. 2) To discuss and approve Service Agreement with NeoDeL Pharma Pvt Ltd. 3) To discuss and approve the change of internal auditors. 4) Any other Business matter, with the permission of the Chair.
18-Jan-2021 23-Jan-2021 Quarterly Results
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.